European Heart Journal - Case Reports · 2020 · 13 citations · 8 references
MedicineInternal MedicinePharmacotherapyClinical ImmunologyImmunopathologyImmunopharmacologyAutoimmune Disease ImmunotherapyAutoimmune DiseasesAutoimmune InflammationCancer ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse EventsAutoimmune Adverse EventsAutoimmune Hepatitis TreatmentCheck Point InhibitorsImmune Checkpoint Inhibitor MyocarditisImmune-mediated MyocarditisNon-small Cell Lung Cancer TherapyPembrolizumab TherapyTroponin Elevation
BACKGROUND: Pembrolizumab is an immune check-point inhibitor (ICI), which acts by blocking the T lymphocyte PD-1 inhibitor receptor. It has been increasingly used in advanced or non-responsive tumours with promising results. However, acute myocarditis is an infrequent but potentially life-threatening autoimmune adverse effect related to ICIs. CASE SUMMARY: This case deals with a 69-year-old gentleman on second-line therapy with pembrolizumab for advanced non-small cell lung cancer. Three weeks after first dose, the patient was diagnosed with an autoimmune hepatitis, treated with decreasing corticoid dosage, followed by acute heart failure. On admission, his electrocardiogram (ECG) showed diffuse repolarization changes and a transthoracic echocardiography revealed severe left ventricle impairment (left ventricular ejection fraction 32%). High-sensitivity cardiac troponin was elevated and a coronary angiogram was performed showing non-significant obstructive disease. An autoimmune myocarditis was suspected, and high-dose intravenous corticoid, intravenous vasodilators, and loop diuretics were started with favourable response. Cardiac magnetic resonance (CMR) imaging, performed 2 weeks after clinical onset, revealed extracellular oedema in the anteroseptal-apical left ventricle segments. A new transthoracic echocardiography, performed after 3 months, showed preserved left ventricle ejection fraction. Finally, the patient was readmitted due to an autoimmune myasthenia-like syndrome. DISCUSSION: Acute autoimmune myocarditis related to ICIs is a challenging diagnosis and its incidence has been underestimated in early studies. Endomyocardial biopsy (EMB) is the gold standard test for its diagnosis. Nevertheless, a definite myocarditis diagnosis is possible without EMB when characteristic clinical syndrome, elevated myonecrosis markers, and electrocardiographic, echocardiographic, and CMR changes are present together.
8
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson, Justin M. Balko, Margaret Compton et al. · New England Journal of Medicine · 2016 · 2.3K citations · Full text
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Hiroyuki Nishimura, Taku Okazaki, Yoshimasa Tanaka et al. · Science · 2001 · 1.9K citations
Life Sciences, Cardiology, Pathology +11